Find in Library

<i>Staphylococcus pseudintermedius</i> is a pathogenic bacterium of concern within the veterinary sector and is involved in numerous infections in canines, including topical infections such as canine pyoderma and otitis externa, as well as systemic infections within the urinary, respiratory and reproductive tract. The high prevalence of methicillin-resistant <i>Staphylococcus pseudintermedius</i> (MRSP) within such infections is a growing concern. Therefore, it is crucial to understand the involvement of <i>S. pseudintermedius</i> in canine disease pathology to gain better insight into novel treatment avenues. Here, we review the literature focused on <i>S. pseudintermedius</i> infection in multiple anatomic locations in dogs and the role of MRSP in treatment outcomes at these niches. Multiple novel treatment avenues for MRSP have been pioneered in recent years and these are discussed with a specific focus on vaccines and phage therapy as potential therapeutic options. Whilst both undertakings are in their infancy, phage therapy is versatile and has shown high success in both animal and human medical use. It is clear that further research is required to combat the growing problems associated with MRSP in canines.